Jun 01, 2020 / 12:00PM GMT
Christian Lawrence Hogg - HUTCHMED(China)Limited-Former CEO&Executive Director
Okay. So I think we're live now. So welcome, everybody, to the Hutchison China MediTech conference call today to talk about ASCO and some of the other things that are going on in our business.
My name is Christian Hogg. I'm the CEO of Chi-Med. I have also on the line Dr. Wei-Guo Su, our Chief Scientific Officer; and Dr. Marek Kania, our Chief Medical Officer, for our international operations based out of New Jersey.
Today, if you go to Page #3 on the presentation, we'll be covering a few subjects. First of all, savolitinib Exon 14 skipping non-small cell lung cancer, the presentation of the registration study data that was presented or that was published today in full on the virtual ASCO site.
Second, Wei-Guo will also take you through the data from the SAVOIR study, the papillary renal cell carcinoma study of savolitinib. And then Marek will take you through the international data, the U.S. data on surufatinib and also give an
Hutchison China MediTech Ltd Investor Update at ASCO Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers